Novel mechanism controlling calcium signaling to treat and prevent neurodegeneration in early stage glaucoma
控制钙信号传导以治疗和预防早期青光眼神经变性的新机制
基本信息
- 批准号:10333217
- 负责人:
- 金额:$ 37.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAcuteAffectAgingAnimal ModelAttenuatedBiologicalBiological ModelsBiomimeticsBlindnessCalcium ChannelCalcium SignalingChronicClinicalClinical ManagementClinical TrialsCombined Modality TherapyComplementComplexDataDefense MechanismsDegenerative DisorderDevelopmentDiseaseDominant-Negative MutationDrug TargetingEye diseasesGlaucomaGoalsHealthHealthcareHeart DiseasesHomeostasisHomer 1Homer 1aImmediate-Early GenesIn VitroInterventionMalignant NeoplasmsMeasuresMinorityModelingMolecularNatureNerve DegenerationNeuronsNeuroprotective AgentsOperative Surgical ProceduresOphthalmologyOptic NervePathogenesisPathologicPatientsPerformancePharmacologic SubstancePharmacotherapyPhysiologic Intraocular PressurePhysiologicalPlant RootsPopulationPre-Clinical ModelProcessProtein IsoformsProteinsPublishingResearchRetinaRetinal Ganglion CellsSecond Messenger SystemsSeverity of illnessSignal TransductionStrategic PlanningSynaptic TransmissionTargeted ResearchTestingTherapeuticTimeTreatment EfficacyUnited StatesVisionVision researchVisualVisual impairmentbasecostdesignexpectationexperimental studyfunctional restorationgene producthealth care deliveryhealth disparityhuman diseaseimprovedin vivoineffective therapiesnerve damageneuroprotectionnormal agingnovelnovel therapeutic interventionpre-clinicalpreservationpreventresponserestorationretinal damageretinal neuronside effecttargeted treatmenttherapeutic targettherapy designtherapy outcometreatment strategyvisual performance
项目摘要
Project Summary/Abstract
The proposal is in response to NEI's strategic plan, described recently by NEI in “Vision Research:
Needs, Gaps, and Opportunities”, and focuses on our most recent discoveries of a novel neuronal
mechanism rooted at the intersection of aging and the biological mechanisms of eye disease identified
as a high programmatic priority. The proposed research targets a novel mechanism of neuroprotection
utilizing intracellular calcium channels as drug targets to treat neurodegeneration in glaucoma.
Specifically, we plan to determine mechanisms of action and to measure preservation of neuronal
viability and function in model systems of glaucoma. The proposed research will allow us to generate
preclinical data needed for the development of novel neuroprotectants to complement existing therapies
targeting intraocular pressure: The intracellular free Ca2+ concentration of retinal ganglion cells like in
other neurons of the CNS is highly regulated and subject to dysregulation during aging. For the
development of acute and chronic degenerative diseases including glaucoma reducing the viability and
function of retinal ganglion cells (RGCs) several studies indicate that both changes in intracellular second
messenger concentration and pathological increases in the intracellular Ca2+ concentration promote
pathogenesis. The present application will test the hypothesis that Ca2+ signaling of RGCs is functionally
regulated by an immediate early gene product upregulated in RGCs after a neurodegenerative insult to
generate a cellular defense mechanism. This hypothesis is based on strong preliminary evidence that
normal aging of the retina is mechanistically similar to glaucoma disease processes and can be exploited
to devise novel treatments for glaucoma. The proposed experiments designed to test this hypothesis will
investigate the molecular, cellular and functional mechanisms underlying this interaction under
experimentally induced disease conditions in models of glaucoma. The overall goal of the proposed
study is to identify a novel mechanism of RGC neuroprotection and determine its potential as a strategy
for neuroprotective therapies targeting RGCs. This therapy approach will have the potential to be both
preventative and therapeutic in nature and to complement existing treatment designs and rationales.
项目概要/摘要
该提案是对 NEI 战略计划的回应,NEI 最近在“视觉研究:
需求、差距和机会”,并重点介绍我们最新发现的一种新型神经元
根植于衰老与眼部疾病生物学机制交叉点的机制
作为高度计划优先事项。拟议的研究针对神经保护的新机制
利用细胞内钙通道作为药物靶点来治疗青光眼的神经变性。
具体来说,我们计划确定作用机制并测量神经元的保存
青光眼模型系统的活力和功能。拟议的研究将使我们能够产生
开发新型神经保护剂以补充现有疗法所需的临床前数据
目标眼压:视网膜神经节细胞的细胞内游离 Ca2+ 浓度,如
中枢神经系统的其他神经元受到高度调节,并且在衰老过程中会出现失调。对于
急性和慢性退行性疾病的发展,包括青光眼,降低活力和
视网膜神经节细胞(RGC)的功能多项研究表明,细胞内第二个细胞的变化
信使浓度和细胞内 Ca2+ 浓度的病理性增加促进
发病。本申请将检验 RGC 的 Ca2+ 信号传导在功能上的假设
神经退行性损伤后,RGC 中立即早期基因产物上调,从而调节
产生细胞防御机制。该假设基于强有力的初步证据,即
视网膜的正常老化在机制上与青光眼疾病过程相似,可以加以利用
设计青光眼的新疗法。旨在检验这一假设的拟议实验将
研究这种相互作用背后的分子、细胞和功能机制
在青光眼模型中通过实验诱发疾病状况。拟议的总体目标
研究旨在确定 RGC 神经保护的新机制并确定其作为策略的潜力
用于针对 RGC 的神经保护疗法。这种治疗方法将有可能同时
本质上是预防性和治疗性的,并补充现有的治疗设计和原理。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies.
- DOI:10.4103/1673-5374.382220
- 发表时间:2024-04
- 期刊:
- 影响因子:6.1
- 作者:Duncan RS;Riordan SM;Gernon MC;Koulen P
- 通讯作者:Koulen P
Novel Machine-Learning Based Framework Using Electroretinography Data for the Detection of Early-Stage Glaucoma.
- DOI:10.3389/fnins.2022.869137
- 发表时间:2022
- 期刊:
- 影响因子:4.3
- 作者:Gajendran, Mohan Kumar;Rohowetz, Landon J.;Koulen, Peter;Mehdizadeh, Amirfarhang
- 通讯作者:Mehdizadeh, Amirfarhang
Analysis of Glaucoma Associated Genes in Response to Inflammation, an Examination of a Public Data Set Derived from Peripheral Blood from Patients with Hepatitis C.
- DOI:10.2147/opth.s364739
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
N-acylethanolamide metabolizing enzymes are upregulated in human neural progenitor-derived neurons exposed to sub-lethal oxidative stress.
- DOI:10.3389/fncel.2022.902278
- 发表时间:2022
- 期刊:
- 影响因子:5.3
- 作者:Duncan, R. Scott;Riordan, Sean M.;Hall, Conner W.;Payne, Andrew J.;Chapman, Kent D.;Koulen, Peter
- 通讯作者:Koulen, Peter
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter Koulen其他文献
Peter Koulen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter Koulen', 18)}}的其他基金
Novel mechanism controlling calcium signaling to treat and prevent neurodegeneration in early stage glaucoma
控制钙信号传导以治疗和预防早期青光眼神经变性的新机制
- 批准号:
10288383 - 财政年份:2020
- 资助金额:
$ 37.59万 - 项目类别:
Novel mechanism controlling calcium signaling to treat and prevent neurodegeneration in early stage glaucoma
控制钙信号传导以治疗和预防早期青光眼神经变性的新机制
- 批准号:
9916194 - 财政年份:2020
- 资助金额:
$ 37.59万 - 项目类别:
Novel mechanism controlling calcium signaling to treat and prevent neurodegeneration in early stage glaucoma
控制钙信号传导以治疗和预防早期青光眼神经变性的新机制
- 批准号:
10190022 - 财政年份:2020
- 资助金额:
$ 37.59万 - 项目类别:
Novel mechanism controlling calcium signaling to treat and prevent neurodegeneration in early stage glaucoma
控制钙信号传导以治疗和预防早期青光眼神经变性的新机制
- 批准号:
10087941 - 财政年份:2020
- 资助金额:
$ 37.59万 - 项目类别:
Novel pro-drug pharmacotherapy to prevent neuronal and cell degeneration in AMD
预防 AMD 神经元和细胞变性的新型前药药物疗法
- 批准号:
10216112 - 财政年份:2019
- 资助金额:
$ 37.59万 - 项目类别:
Novel pro-drug pharmacotherapy to prevent neuronal and cell degeneration in AMD
预防 AMD 神经元和细胞变性的新型前药药物疗法
- 批准号:
10213749 - 财政年份:2019
- 资助金额:
$ 37.59万 - 项目类别:
Novel pro-drug pharmacotherapy to prevent neuronal and cell degeneration in AMD
预防 AMD 神经元和细胞变性的新型前药药物疗法
- 批准号:
10018027 - 财政年份:2019
- 资助金额:
$ 37.59万 - 项目类别:
Novel mechanism of action as therapeutic strategy for optic neuritis
作为视神经炎治疗策略的新作用机制
- 批准号:
8675259 - 财政年份:2012
- 资助金额:
$ 37.59万 - 项目类别:
Novel mechanism of action as therapeutic strategy for optic neuritis
作为视神经炎治疗策略的新作用机制
- 批准号:
8511676 - 财政年份:2012
- 资助金额:
$ 37.59万 - 项目类别:
Novel mechanism of action as therapeutic strategy for optic neuritis
作为视神经炎治疗策略的新作用机制
- 批准号:
8366675 - 财政年份:2012
- 资助金额:
$ 37.59万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 37.59万 - 项目类别:
Operating Grants